A previous work reported that Aβ biomarkers’ positivity had been detected in 20 to 30% of cognitively normal individuals and also that patients with non-AD dementias (such as FTD) could present positive amyloid-PET, especially elderly cases carrying an APOE ε4 allele [68]. This evidence concerns the gene APOE and frontotemporal dementia.